Trial Condition(s):

Pain, postoperative

Evaluate analgesic / sedative efficacy of Naproxen sodium and diphenhydramine in patients with Postsurgical Dental Pain (Morpheus/DPH)

Bayer Identifier:

15881

ClinicalTrials.gov Identifier:

NCT01495858

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of the study is to evaluate the efficacy and safety of a single oral dose of naproxen sodium 440 mg in combination with DPH (diphenhydramine) 25 mg in subjects with postsurgical dental pain and phase advanced sleep.

Inclusion Criteria
- Healthy, ambulatory, male and female volunteers ages 12 and older
 - Scheduled to undergo surgical removal of a minimum of two third molars of which at least one has to be a mandibular third molar. The mandibular extraction(s) required by each subject must meet one of the following scenarios:
 -- one full bony impaction
 -- two partial bony impactions
 -- one full bony impaction and one partial bony impaction
 -- one full bony impaction and one soft tissue impaction
 -- one full bony impaction and one erupted third molar. Two full bony mandibular impactions are not allowed. Maxillary third molars may be removed regardless of impaction level.
 - Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale between 1600 hour and 1830 hour on the day of surgery
 - Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy.
Exclusion Criteria
- History of hypersensitivity to naproxen, diphenhydramine, nonsteroidal anti-inflammatory drug (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products
 - Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years
 - Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator
 - Current or past history of bleeding disorder(s)
 - Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator
 - Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months
 - Positive alcohol breathalyzer test and positive urine drug test prior to surgery
 - Females who are pregnant or lactating
 - Chronic or severe sleep problems that do not respond to Over the Counter (OTC) medication and requires a prescription hypnotic or sedative
 - Habitually spends less than 6.5 hours in bed

Trial Summary

Enrollment Goal
267
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Aleve PM (BAY98-7111)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Pharmaceutical Product Development, LLC

Austin, United States, 78744

Status
Completed
 
Locations

Lifetree Clinical Research

Salt Lake City, United States, 84106

Status
Completed
 

Trial Design